Grant: CIHR Fellowship
Direct Payment
$100,000.00
Self-renewal Programs in Rhabdomyosarcoma
FY 2017-18
Summary
Relapse is a major clinical problem facing pediatric patients with rhabdomyosarcoma (RMS), a devastating malignancy of the muscle. In RMS, populations of undifferentiated cells with stem-like properties drive relapse and if these cells could be eliminated, tumors would regress and patients could remain relapse free. In the Langenau lab, I am utilizing zebrafish, human and mouse xenograft models of RMS to understand biological mechanisms relating to relapse.
I have identified an important role for Van Gogh-like 2 (Vangl2), a core regulator of the non-canonical Wnt/Planar cell polarity (Wnt/PCP) signaling pathway in growth and self-renewal of RMS. I have discovered that VANGL2 is expressed in a majority of primary patient RMS and that VANGL2 depletion inhibits tumor cell proliferation and reduces self-renewal. Using a powerful zebrafish model of embryonal rhabdomyosarcoma (ERMS) developed in the Langenau lab, I identified that Vangl2 expression enriches for self-renewing tumor cells and when over-expressed, elevates their number >9-fold. Further mechanistic studies reveal a role for RhoA downstream of Vangl2, identifying targetable pathways for potential patient treatment.
Previous work has linked Wnt/PCP signaling to growth, invasion and metastasis. However, my work will be the first to assess Wnt/PCP signaling in the self-renewal of tumor cells, offering novel opportunities to isolate and characterize relapse mechanisms involved in human cancer.
Department
Program
CIHR Fellowship
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
376605
Name
Hayes Madeline
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Self-renewal Programs in Rhabdomyosarcoma
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Developmental Signaling Pathways; Pediatric Oncology; Rhabdomyosarcoma; Self-Renewal; Translational Animal Models; Zebrafish Cancer Models
Abstract
Relapse is a major clinical problem facing pediatric patients with rhabdomyosarcoma (RMS), a devastating malignancy of the muscle. In RMS, populations of undifferentiated cells with stem-like properties drive relapse and if these cells could be eliminated, tumors would regress and patients could remain relapse free. In the Langenau lab, I am utilizing zebrafish, human and mouse xenograft models of RMS to understand biological mechanisms relating to relapse.
I have identified an important role for Van Gogh-like 2 (Vangl2), a core regulator of the non-canonical Wnt/Planar cell polarity (Wnt/PCP) signaling pathway in growth and self-renewal of RMS. I have discovered that VANGL2 is expressed in a majority of primary patient RMS and that VANGL2 depletion inhibits tumor cell proliferation and reduces self-renewal. Using a powerful zebrafish model of embryonal rhabdomyosarcoma (ERMS) developed in the Langenau lab, I identified that Vangl2 expression enriches for self-renewing tumor cells and when over-expressed, elevates their number >9-fold. Further mechanistic studies reveal a role for RhoA downstream of Vangl2, identifying targetable pathways for potential patient treatment.
Previous work has linked Wnt/PCP signaling to growth, invasion and metastasis. However, my work will be the first to assess Wnt/PCP signaling in the self-renewal of tumor cells, offering novel opportunities to isolate and characterize relapse mechanisms involved in human cancer.
Competitiondate
201711
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Hayes, Madeline
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~